Similar to CTSB, CRC patients with high expression of ARL4C often showed poor survival rates and studies suggested that ARL4C could be used as a new therapeutic target to inhibit the proliferation and invasion of CRC cells. Here, ARL4C is linked to colorectal carcinoma.